

Introduction

The objective of this Policy is to maintain the integrity and transparency of financial relationships as they may relate to Investigators' research at AbVacc, Inc. ("**Company**"). To accomplish our purpose, all Investigators (defined below) must complete a Significant Financial Interest Disclosure Form ("**SFI Disclosure Form**") at least annually disclosing all of their Significant Financial Interests ("**SFI**") (defined below).¹

This Policy applies to all federal Public Health Service ("**PHS**")-funded research, and is consistent with the financial conflict of interest regulation promulgated by the Department of Health and Human Services ("**DHHS**"), as revised in 2011 ("**Regulation**").

Recipients of research funds from sources other than PHS must comply with the conflict of interest requirements of the funding source.

Irrespective of funding source, Investigators must disclose all of their SFI, as requested, including during the Company's annual disclosure cycle. These disclosures enable the Company to initiate its conflict of interest review, as needed.

Investigators who are responsible for the design, conduct, or reporting of research are required to disclose their SFI prior to submitting a PHS grant application, and must update disclosures within thirty (30) days of discovering or acquiring any new SFI. The Company's Financial Conflict of Interest Committee ("**Committee**") determines whether the disclosed SFI is related to the Investigator's PHS-funded research, and, if related, whether the SFI creates a financial conflict of interest ("**FCOI**"). If a conflict exists, assistance will be provided to eliminate, reduce, or manage the conflict.

Definitions

The following definitions track those in the Regulation.

Investigator

Investigator means the Project Director or Principal Investigator and any person in or collaborating or consulting with a laboratory, regardless of title or position, who is responsible for the design, conduct, or reporting of research.

Financial conflict of interest (FCOI)

A financial conflict of interest exists when an Investigator's SFI could directly and significantly affect the design, conduct, or reporting of the Investigator's research.

Significant Financial Interest (SFI)

A significant financial interest means a financial interest consisting of one or more of the following interests of the Investigator (and her/his spouse and dependent children) that reasonably appear to be related to the Investigator's Institutional Responsibilities:

1. Publicly traded entities: (a) all remuneration (e.g., salary, consulting fees, honoraria, paid authorship) from the entity in the 12 months prior to disclosure, and (b) equity (e.g., stock, stock options, other ownership interest) held as of the date of the disclosure, that (c) when combined (remuneration + equity) exceeds \$5,000;
2. Non-publicly traded entities: (a) all remuneration from the entity in the 12 months prior to disclosure that, when combined, exceeds \$5,000, or (b) any equity interest in the entity;
3. Intellectual property rights and interests (e.g., patents, copyrights), upon receipt of payments in excess of \$5,000 from any source other than the Company, received in the 12 months prior to disclosure;
4. Reportable travel includes any reimbursed or sponsored travel in the 12 months preceding disclosure. Sponsored travel includes travel that is paid on behalf of the Investigator but not reimbursed directly, so that the exact monetary value may not be known by the Investigator. In such circumstances, an estimate of the sponsored travel must be disclosed. Investigator disclosures must specify the purpose of the trip, the identity of the sponsor/organizer, the destination, and the trip's duration.
 - Travel that need not be reported includes travel reimbursed or sponsored by a federal, state, or local government agency, a U.S. institution of higher education, an academic teaching hospital, a medical center, or a research institute that is affiliated with a U.S. institution of higher education.

SFI does not include:

- Salary, royalties, or other remuneration from the Company
- Income from investments such as mutual funds or retirement accounts so long as the Investigator does not directly control these vehicles' investment decisions; or
- Income from seminars, lectures, teaching engagements, service on advisory committees, or review panels for a federal, state, or local government agency, a U.S. institution of higher education, an academic teaching hospital, a medical center, or a research institute affiliated with a U.S. institution of higher education.

Faculty Conflict of Interest Committee

The Committee, composed of members of the Company faculty, has authority to determine whether an Investigator's SFI creates a financial conflict of interest. If so, the Committee works with the Investigator to eliminate, reduce, or manage the conflict by implementing a management plan.

Institutional Responsibilities

Institutional responsibilities means an Investigator's professional responsibilities on behalf of the Company which may include, for example, activities such as research, research consultation, teaching, professional practice, institutional committee memberships, and service on panels such as the Company's IRB or a Data and Safety Monitoring Board.

Investigator Disclosures

Each Investigator must update his or her SFI Disclosure Form:

- at least annually;
- within 30 days of acquiring a new SFI, including reportable travel;
- within 30 days of discovering previously unreported SFI; and
- when the Investigator initiates any new PHS-funded research project, or is added to the list of investigators on an ongoing PHS-funded research project.

As a condition of submitting a grant application to a PHS awarding agency, each Investigator named on the grant application must have completed an SFI Disclosure Form reporting all SFI received in the preceding 12 months.

Sub-Recipient Disclosures

If research is done on behalf of the Company through institutional sub-recipients, the Company will incorporate, as part of a written agreement with the sub-recipient, terms that establish whether the Company's or the sub-recipient's FCOI policy will apply to the sub-recipient's Investigators. Additionally, the written agreement should address the time frames within which the sub-recipient must provide either (i) FCOI information necessary to ensure that the Company is able to meet its FCOI reporting obligations to the PHS awarding agency, or (ii) financial disclosure information to enable the Company to comply timely with its review, management, and reporting obligations under the Regulation.

- If a sub-recipient defers to the Company's FCOI Policy, the individuals at the sub-recipient involved in the design, conduct, or reporting of the research are considered Investigators as defined in the Company FCOI Policy.
- If a sub-recipient's policy applies, the sub-recipient must certify that its policy complies with the Regulation.

Procedures for Determining and Addressing Conflict

No awarded PHS funds can be expended until all FCOI related to a grant have been eliminated, reduced, or managed.

The Committee oversees and manages implementation of this Policy. The administrative office of the Committee will review each SFI Disclosure Form to determine: (a) whether reported SFI reasonably appears to be related to the Investigator's PHS-funded research and/or other Institutional Responsibilities, *and*, (b) if related, whether the SFI could directly and significantly affect the design, conduct, or reporting of the research. If the answer to both (a) and (b) is "Yes", an FCOI may be found to exist.

If the Committee determines that the Investigator has an FCOI, the Committee will work with the Investigator on a management plan to eliminate, reduce, or manage the conflict. Management plan elements may include, but are not limited to, requiring the Investigator to disclose the potential FCOI to laboratory or study team members working on the research, to research participants, and/or to publishing journals; establishing independent review of research data; and/or requiring the Investigator to relinquish the SFI. The Company will monitor the Investigator's compliance with each imposed management plan on an ongoing basis until completion of the PHS-funded research project.

To the extent that a new or previously unreported SFI is disclosed during the course of PHS-funded research (*e.g.*, an Investigator who is new to the research project discloses SFI or a previously named Investigator discloses new or previously unreported SFI), the Committee will, within 60 days from the date of the disclosure, determine whether an FCOI exists, and, if so, will implement a plan to eliminate, reduce, or manage the conflict.

If an FCOI is not identified or managed as required, due to (i) a failure by an Investigator to timely disclose SFI that is later determined by the Committee to constitute an FCOI, (ii) the Company's failure to review or manage such an FCOI, or (iii) an Investigator's failure to comply with an FCOI management plan, the Company will, within 120 days of its determination of noncompliance, complete a retrospective review of the Investigator's activities and PHS-funded research to determine whether the design, conduct, or reporting of the research has been affected by bias. The Company will document the retrospective review, including, at a minimum, (i) the project number and title, (ii) the Investigator's name and the entity creating the FCOI, (iii), the Principal Director/Principal Investigator contact information, (iv) the reason(s) for the review, (v) the detailed methodology used for the review, and (vi) the findings and conclusions. The Company will notify the PHS awarding agency of any bias found in the PHS-funded research and will submit a mitigation report that addresses the impact of the bias on the research project and the Company's plan to eliminate or mitigate the effect of the bias.

The Company will maintain records of all Investigator disclosures of financial interests and all actions under this FCOI Policy. Records will be kept for at least three years from the date that the final expenditure report is submitted to the PHS awarding agency, or, when applicable, as specified in 45 C.F.R. Sections 74.53(b) and 92.42(b) for different situations.

If DHHS determines that a PHS-funded clinical research project whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment has been designed, conducted, or reported by any Investigator with an FCOI that was not managed or reported as required by the Regulation, the Company will require the Investigator to disclose the FCOI in each public presentation of the results of the research and to request an addendum to her or his previously published presentations.

Reporting Financial Conflict of Interests

Prior to the Company's expenditure of awarded PHS funds, the Company is required to report to the PHS awarding agency the existence of any FCOI, including FCOI of sub-recipient Investigators management plan(s) and to submit an FCOI report to the awarding agency. The Company also must submit annual FCOI reports to the PHS awarding agency during the award period. These annual reports must address the status of the FCOI, e.g., whether the FCOI is being managed, any changes to the management plan, and/or if the FCOI no longer exists. Annual reports must be made for the duration of the research project period (including extensions with or without funds) in the time and manner specified by the PHS awarding agency.

The Company must also submit FCOI reports to the PHS awarding agency within 60 days of identifying any previously unreported FCOI.

Within five (5) business days of receiving a written request from the public for information about PHS-funded research involving an Investigator with an FCOI, the Company will respond to the request in writing, providing the name of the Investigator, the entity in which the Investigator holds SFI, the nature of the SFI, and the approximate value of the SFI, in dollar ranges, if known.

Final Company Financial Conflict of Interest Authority

If the Committee is unable to reach agreement with an Investigator on an appropriate plan to eliminate, reduce, or manage an FCOI, the Committee will provide the Investigator with a written impasse letter. Within two weeks of the date of the written impasse letter, the Investigator or the Committee shall seek the intervention of the Company President.

The President will address the conflict and render a decision on its resolution. The President's decision is final, except that it does not extend to the decisions and actions of the Company's IRB in carrying out its independent function of protecting human study participants in clinical research.

Training

Each Investigator must be trained on this Policy, the Investigator's responsibilities regarding SFI disclosure, and the requirements of the Regulation. Each Investigator must complete this training (i) prior to engaging in any PHS-funded research, (ii) at least every four years, and (iii) immediately in any of the following circumstances:

- the Investigator is new to the Company;
- the Company revises this Policy in any manner that affects the requirements applicable to Investigators; or
- the Company finds that an Investigator is not in compliance with this Policy or with the Investigator's FCOI management plan.

Noncompliance and Sanctions

In the event an Investigator fails to comply with this Policy or a previously imposed FCOI management plan, the Committee shall recommend appropriate sanctions that may include, for example, imposing a stricter management plan, withholding a PHS grant application, suspending an ongoing PHS-funded research project, freezing PHS project funds, and/or other appropriate sanctions.

Conflict of Commitment in Research

This conflict of commitment in research policy has been adopted by the Company and is not subject to external requirements.

Investigators' external activities should not interfere with the primary professional commitment of their time and intellectual energies to the education and research programs of the Company.

Up to 52 days per year may be devoted to external activities provided that an investigator's Company work is not adversely affected. Government service and service with not-for-profit institutions do not count against the guideline stated here.

Company doctoral students, postdoctoral appointees, and instructors in clinical investigation are not permitted to engage in extramural activities for compensation.

Requests to engage in activities outside of these guidelines should be addressed to the President or his or her designee and may be approved if extraordinary circumstances warrant.

Consulting arrangements with outside entities cannot compromise the Company's rights to intellectual property as established in Company policy.

Entities outside the Company may not impose restrictions on investigators' rights to disseminate results of research performed at the Company in published or other form, except for reasonable delays not to exceed ninety (90) days to allow for patent processing.



Project Title: _____

Disclosing Investigator: _____

Role in Research: _____

Phone: _____

Email: _____

Principal Investigator: _____ Sponsor: _____

Name(s) of personnel who are responsible for the design, conduct or reporting on any of the proposed research, including non-AbVacc Investigators (domestic and foreign) such as collaborators, sub-recipients, or subcontractors proposed for funding: _____

Is this research funded by Public Health Service (PHS) grants and/or cooperative agreements?

- Yes
- No
- Funding application planned/currently under review

Any scientific element or segment of the project that is being conducted outside of the U.S., regardless of whether the foreign component will receive funding from the sponsored research application: _____

Does a foreign component provide the Principal Investigator or any research team members with any resources or financial support, access to, or in-kind support for laboratory space, research materials, supplies, equipment or staff participation: _____

Disclosure

- Initial Disclosure
- Ad Hoc Disclosure

1. **Have you or a family member received remuneration for services in the past 12 months or own equity interest in any publicly traded entity, domestic or foreign, that might reasonably be related to your Investigator responsibilities, and which exceeds \$5,000 when aggregated?**

Note: Remuneration includes salary and any payment for services not otherwise identified as salary, such as consulting fees, honoraria, and paid authorship. Equity interests include stocks, stock options, or other ownership interests, as determined through reference to public prices or other reasonable measures of fair market value. This does not include interests in mutual funds and retirement funds in which you do not directly control investment decisions.

- Yes
- No

2. **Have you or a family member received remuneration for services in the past 12 months from any non-publicly traded entity, domestic or foreign, that might reasonably be related to your Investigator responsibilities, and which exceeds \$5,000 when aggregated? If there is no reasonable basis for assessing the fair market value or percentage interest in the non-publicly traded entity, please fully describe the nature of the equity interest, including the number of shares owned, voting rights, etc.**

Note: Equity interests include stocks, stock options, or other ownership interests. This does not include payments or income from seminars, lectures, or teaching engagements sponsored by a government agency, a U.S. institution of higher education or affiliated research institute, an academic teaching hospital, or a medical center.

- Yes
- No

3. **Have you or a family member received any payments in the past 12 months for any patents, copyrights, know-how or other intellectual property rights (e.g. royalties, license fees, equity or other consideration) that might reasonably be related to your Investigator responsibilities and which exceeds \$5,000 when aggregated?**

Note: Disclosure is not required for royalties, fees or other consideration paid to the Investigator by AbVacc for intellectual property owned by AbVacc (e.g., not personally owned by the Investigator).

- Yes
- No

4. **Do you or a family member have any advisory relationship, consulting, outside teaching, or scientific/academic appointment including adjunct, visiting or honorary, with any domestic entity (other than AbVacc), both paid and volunteer, as well as any unpaid appointment that provides you with access to, or in-kind support for, laboratory space, research materials, supplies, equipment, staff participation or living expenses?**

Note: Disclosure is not required for the following:

- a. Salary or other remuneration received from AbVacc if the Investigator is currently employed or appointed by AbVacc.
- b. Income from seminars, lectures, or teaching engagements sponsored by a U.S. federal, state or local government agency, a U.S. institution of higher education, a U.S. academic teaching hospital, a U.S. medical center or a U.S. research institute that is affiliated with

a U.S. institution of higher education as defined in 20 U.S.C. 1001(a).

- c. Income from service on advisory committees or review panels for a U.S. federal, state or local government agency, a U.S. institution of higher education, a U.S. academic teaching hospital, a U.S. medical center or a U.S. research institute that is affiliated with a U.S. institution of higher education as defined in 20 U.S.C. 1001(a).

- Yes
 No

5. **Do you or a family member have any relationship with a foreign entity or government including, but not limited to, any involvement with a government talent recruitment program or similar-type program, both paid and volunteer, and any position or scientific appointment stemming from a foreign government, which includes local, provincial or equivalent governments, government agencies, institutions of higher education, academic teaching hospitals, medical centers, or research institutes that are affiliated with an institution of higher education that might reasonably be related to your Investigator responsibilities?**

- Yes
 No

6. **Have you or a family member received any reimbursed expenses, gifts, gratuities, favors, lodging, or entertainment offers in the past 12 months that might reasonably be related to your Investigator responsibilities and which exceeds \$5,000 when aggregated?**

Note: Investigators may not solicit or accept reimbursed expenses, gifts, gratuities, favors, lodging, or excessive entertainment for themselves, his/her spouse or domestic partner or dependent children, alone or in combination, or for any person or organization that does business or has the potential of doing business with AbVacc. Exempt from this prohibition are non-cash gifts of nominal value involving normal and ordinary social amenities or sales promotions.

- Yes
 No

7. **Have you or a family member received any sponsored or reimbursed travel within the United States in the past 12 months that might reasonably be related to your Investigator responsibilities and which exceeds \$5,000 when aggregated?**

Note: Disclosure is not required for Sponsored/Reimbursed Travel stemming from a U.S. federal, state, or local government agency, a U.S. institution of higher education as defined in 20 U.S.C. 1001(a), a U.S. academic teaching hospital, a U.S. medical center, or a U.S. research institute that is affiliated with a U.S. institution of higher education.

- Yes
 No

8. **Have you or a family member received any sponsored or reimbursed travel outside the United States in the past 12 months that might reasonably be related to your Investigator responsibilities?**

Note: Regardless of dollar amount. Foreign entities include, but are not limited to, those stemming from a foreign company or government, including local, provincial or equivalent governments, government agencies, institutions of higher education, academic teaching hospitals, medical centers, or research institutes that are affiliated with an institution of higher education.

- Yes
 No

Certification

I certify that I have read, understand and will abide by the AbVacc's Financial Conflict of Interest (FCOI) Policy, have answered truthfully, and to the best of my knowledge have made all required disclosures.

Signature of Disclosing Investigator

Date

Appendix Form

If you responded “Yes” to any of the above questions, please provide a detailed explanation below.

If you are disclosing travel, please provide the following information:

- a. The identity of the sponsor/organizer.
- b. The month and year of the travel.
- c. The financial value by range of the travel.
- d. The value of any associated honorarium.
- e. The purpose of the travel.
- f. The destination of the travel.
- g. The time duration of the travel.